抗中性粒细胞胞质抗体相关性血管炎治疗进展  

New advance of therapy in antineutrophil cytoplasmic antibody-associated vasculitides

作　　者：胡子盈 帅宗文[1] 

机构地区：[1]安徽医科大学第一附属医院风湿免疫科,合肥230000

出　　处：《中华临床医师杂志（电子版）》2014年第11期110-116,共7页Chinese Journal of Clinicians(Electronic Edition)

基　　金：中华医学会临床医学科研专项资金项目(08010290107)

摘　　要：随着大量针对抗中性粒细胞胞浆抗体(ANCA)相关性血管炎(AAV)临床试验的开展,对其治疗逐渐达成共识:目前AAV的治疗主要分为诱导缓解,维持缓解和复发治疗,环磷酰胺和糖皮质激素仍然是主要的治疗手段,甲氨蝶呤、霉酚酸酯、美罗华、硫唑嘌呤、血浆置换等的治疗价值也得到了进一步的肯定和定位,AAV治疗更趋于个体化。最近,基于对AAV发病机制研究的不断深入,以淋巴细胞和细胞因子为靶向的新的治疗手段,有望进一步改善患者愈后。Along with the development of great amounts of the clinical trials of antineutrophil cytoplasmic antibody associated vasculitis（AAV）, a consensus of its treatment is gradually reached that the treatment of AAV mainly includes remission induction, maintainable remission and treatment of recurrent AAV. Main treatments are cyclophosphamide and glucocorticoid. The therapeutic value of methotrexate, mycophenolate mofetil, rituximab and plasmapheresis also gains further recognition and positioning. AAV treatment tends to be individualization. Recently, the continuously deeper study based on AAV pathogenesis and the new treatment targeting the lymphocyte and cytokines are likely to further improve the prognosis for patients.

关 键 词：抗体 抗中性白细胞胞质 血管炎 免疫抑制剂 生物制品 临床治疗 

分 类 号：R593[医药卫生—内科学]